Abbott Infinity DBS family. Credit: Abbott.

The US Food and Drug Administration (FDA) has granted approval to Abbott to upgrade the software of its Infinity Deep Brain Stimulation (DBS) System designed to treat patients with Parkinson’s disease and essential tremor.

The over-the-air upgrade is set to add magnetic resonance (MR)-conditional labelling and various advanced features to the DBS device.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Before the upgrade, patients using DBS therapy could not access these features due to the potential requirement for an MRI in the future.

“The Infinity DBS system comprises directional leads that send stimulation to target areas of the brain in order to enhance patient outcomes and minimise side effects.”

The approved labelling will allow the use of the improved Infinity device, which is said to be the first FDA-cleared MR-conditional directional DBS system.

Existing implanted Infinity systems can be upgraded through secure Bluetooth wireless technology, eliminating the need for surgery.

Abbott movement disorders medical director Binith Cheeran said: “With this software upgrade, Abbott delivers on a promise to develop powerful features that strengthen the Infinity DBS system’s already patient-centric platform, which uses familiar Apple technology and frees the patient from recharging their device.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are committed to continued innovation in neuromodulation, developing ongoing advancements and efficiencies for physicians and, most importantly, helping thousands of people who are battling movement disorders live fuller lives.”

The Infinity DBS system comprises directional leads that send stimulation to target areas of the brain in order to enhance patient outcomes and minimise side effects.

Abbott designed the device to support any capability upgrades and the addition of new therapy features via simple, over-the-air updates.

The system also has the European CE-Mark, along with approvals in around 30 other countries such as Russia, Saudi Arabia and Taiwan.